Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic
1 OR Design Unit, University of Sydney, Nepean Hospital, PO Box 63, Penrith NSW 2750, Australia
2 Eucanol Pty Ltd, Wollongong, NSW, Australia
3 University of Kiel, Germany
BMC Surgery 2001, 1:1 doi:10.1186/1471-2482-1-1Published: 16 May 2001
Antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE, are an increasing problem world-wide, causing intractable wound infections. Complex phytochemical extracts such as tea tree oil and eucalypt-derived formulations have been shown to have strong bactericidal activity against MRSA in vitro. Polytoxinol (PT) antimicrobial, is the trade name of a range of antimicrobial preparations in solution, ointment and cream form.
We report the first use of this drug, administered percutaneously, via calcium sulphate pellets (Osteoset,TM), into bone, to treat an intractable MRSA infection of the lower tibia in an adult male.
Results and Discussion
Over a three month period his symptoms resolved with a healing response on x-ray and with a reduced CRP.